Clinical Trial Update: Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery [Phase 1]

View source ↗

Summary

This clinical trial update reports results from a Phase 1 study of Copper-64 TP3805 PET imaging to detect cancer in men with prostate cancer undergoing surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Cu-64 TP3805 (Copper-64 TP3805)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Prostate Adenocarcinoma, Stage IIB Prostate Cancer | Phase 1 | Status: COMPLETED